Genomic testing

Do You Actually Need — Comprehensive Genomic Profiling?

A full genomic panel tests hundreds of tumour genes at once. It is also one of the more expensive tests your team can order. For many patients, a smaller targeted test answers the same clinical questions for considerably less.

Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed September 2026

Most patients do not need it — Common cancers have a known, small set of relevant genes. A targeted panel covers them.
CGP has specific indications — It adds real value for rare cancers, unknown primary, and when standard options are exhausted.
More results is not better results — A longer report often includes many variants with no current treatment implication.
Test selection is a clinical decision — Your oncologist decides which test is appropriate based on your cancer type and what needs answering.

Book Free Consultation 1800 202 8726

4.8 · 800+ Google reviews · 15,000+ patients treated

17+

Cancer Specialists
on Panel

96.9%

Breast Cancer
Survival Rate*

15,000+

Patients
Treated

4.8★

Google Rating
(800+ reviews)

Comprehensive genomic profiling tests hundreds of genes at once. Most patients do not need it — a smaller, cancer-specific panel covers the decisions that guide treatment for the majority of cases and costs considerably less. Whether the full panel is justified depends on your cancer type, stage, and what has already been tested.

What does comprehensive genomic profiling mean?

Comprehensive genomic profiling (CGP): A test that reads hundreds of genes in your tumour at once, looking for mutations, gene copy changes, and structural rearrangements across a large portion of the genome.
Targeted gene panel: A test checking a specific list of genes — typically 20 to 50 — known to drive your cancer type. Less information, lower cost, and faster results than CGP.
Biomarker: A measurable feature of the tumour — a mutation, protein level, or DNA repair pattern — that predicts whether a specific treatment is likely to help you.
Actionable mutation: A genetic change for which a treatment exists or a clinical trial is open. Not every mutation a test finds is actionable, and a longer report does not mean more actionable findings.
Variant of uncertain significance (VUS): A genetic change the laboratory detected where the evidence does not yet confirm whether it drives the cancer or can be targeted. VUS findings are common in full panels and rarely change the treatment plan.

Who actually needs a full genomic panel?

The patients who genuinely benefit are those with rare or unusual cancers, cancers of unknown primary, or cancers that have stopped responding to standard treatment. In these situations, CGP can reveal a mutation that a targeted panel would have missed and that points to an alternative treatment.

For most patients with common cancer types, the clinically relevant genes are well established and a targeted panel covers them. CGP adds a longer result and a larger bill without, in most cases, changing the treatment recommendation.

If your oncologist has recommended CGP, ask what specific gene or clinical question the full panel is intended to answer. That tells you what you are waiting for and what a result would change.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile

Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile

Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile

Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile

Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile

Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile

Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile

Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile

Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile

Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile

Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile

Interventional Radiologist

Dr. Mohammed Imran

View Profile

Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile

Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

What is the difference between a full panel and a targeted panel?

	Comprehensive genomic profiling	Targeted gene panel
Genes tested	Hundreds — covers most known cancer genes	20 to 50 — specific to your cancer type
Best suited for	Rare cancers, unknown primary, after standard options	Common cancers with established driver genes
Typical turnaround	Two to four weeks	One to two weeks
Indicative cost (2025)	Significantly higher — confirm with your billing team before ordering	Moderate — varies by panel and laboratory
What the report contains	Long list of variants, many without current treatment implications	Focused report on genes guiding your immediate treatment decisions
How often it changes the plan	A minority of cases — highest yield in rare and refractory cancers	Covers what is needed for most patients at first treatment

When is a targeted panel likely to be enough?

Your cancer type has a small, well-known set of actionable genes that standard panels already cover.
You are at first treatment and have not yet tried the established options for your cancer.
Your oncologist has not raised concerns about a rare presentation or unknown primary.
The specific markers driving your treatment decision — such as MSI or PD-L1 — are tested separately and do not require a full panel.
Your biopsy sample is small; targeted panels require less tissue and are more likely to give a result.
Some testing has already been done — confirm what was covered before ordering more.

What should I ask before my team orders a genomic test?

My oncologist has recommended CGP. Should I question it?

Do not push back, but do ask why. If your oncologist has recommended CGP, there is likely a specific reason — an unusual tumour presentation, a guideline recommendation for your cancer type, or a decision that a smaller panel cannot resolve. Ask what gene or clinical question the full panel is intended to answer. That tells you what a result would change and what you are waiting for while the sample is in the laboratory.

Can I ask for CGP if my oncologist has not offered it?

You can ask, and your oncologist will hear the question. What they will explain is whether your cancer type and situation are ones where CGP is likely to add information that changes the plan. If it is not, they are not withholding something — they are protecting you from a significant cost and a lengthy report full of findings that will not guide treatment. The more useful question to ask is: what test are you ordering, and what will it tell us?

What happens if the full panel finds something?

Most findings fall into three categories: variants that are clearly actionable, variants of uncertain significance, and variants with no current treatment implication. A long report with many uncertain variants is not the same as a useful result. Ask your oncologist to go through the findings that have treatment implications — what they are, what they mean, and whether they change the plan. You need to understand the findings that affect the next decision, not every variant in the report.

Does insurance cover genomic testing in India?

Coverage under government health schemes and private insurance is variable and often limited. CGP is sometimes covered when ordered by a registered oncologist for a specific indication. Confirm coverage with the billing team before the sample is sent to the laboratory — not after. The cost of a panel ordered without coverage confirmation falls to the family, and that conversation is considerably harder once testing is underway. Some laboratories also offer payment plans; ask at the time of ordering.

Is a liquid biopsy the same as a genomic panel?

No. A liquid biopsy is a blood test that detects tumour DNA circulating in the bloodstream. It can identify specific mutations but is less sensitive than a tissue sample, because the amount of available DNA is smaller. Some panels can be run on liquid biopsy when tissue is unavailable or too small for a tissue-based test, but liquid biopsy is not a replacement for tissue testing and is not the same as comprehensive genomic profiling. Your oncologist will advise which sample type the test requires.

Explore 112 more Markers, Molecular Testing and Test Accuracy topics

Molecular & Genomic Testing

Breast Markers: ER, PR, HER2, Ki-67

False Negatives & Accuracy

IHC Markers Explained

Inadequate, Inconclusive & Repeat Biopsy

Labs, Slides, Blocks & Second Opinions

All Markers, Molecular Testing and Test Accuracy →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726

Common questions

Frequently asked questions

What is comprehensive genomic profiling in simple terms?

It is a laboratory test that reads the DNA of your tumour and looks for changes across hundreds of genes at once. The aim is to find mutations that a specific treatment could target. It gives more information than a targeted panel, but more information is not always more useful — many variants found in a full panel have no current treatment implication and will not change your plan.

How do I know if my oncologist ordered the right test?

Ask which genes the test covers and what clinical question it answers for your cancer type. If a targeted panel was ordered, ask whether it includes the markers relevant to your situation. If a full panel was ordered, ask what a targeted panel would have missed. A clear explanation in plain terms is reasonable to expect, and asking for it in writing is also reasonable.

Can I get the result explained in plain language?

Yes, and you should ask for that. Genomic reports are written for clinicians, not patients. Ask your oncologist to go through the findings that have treatment implications — what they are, what they mean, and whether they change the plan. You do not need to understand every variant in the report; you need to understand the ones that affect the next decision.

What does 'variant of uncertain significance' mean?

It means the laboratory found a genetic change that is real, but the evidence does not yet confirm whether it drives the cancer or can be targeted with a treatment. VUS findings are common, especially in full panels. They are not a reason for alarm and do not usually change the treatment plan. Some are reclassified over time as evidence accumulates — your team may revisit them if guidelines change.

How long does genomic testing take?

A targeted panel usually returns results within one to two weeks from when the laboratory receives the sample. Comprehensive genomic profiling typically takes two to four weeks, and sometimes longer if the sample must go to a specialist laboratory. If you are waiting for a result before starting treatment, ask whether a preliminary test can inform the first decision while the full result is pending.

Can CGP predict whether I will respond to treatment?

It can identify whether your tumour carries a mutation that a specific treatment is designed to target, and that is a meaningful predictor of response. It cannot guarantee a response. Genomic testing informs the probability — it does not make the decision. Your oncologist uses the result alongside your stage, general health, and prior treatment history to recommend the plan most likely to help you.

Full index